Dabigatran Risks: Study Shows Pradaxa Could Be Dangerous For Pregnant Women
Researchers in Canada have issued a warning pertaining to the possible dabigatran risks when the drug is used as an anticoagulation treatment in pregnant women. According to scientists, dabigatran, also known as Pradaxa, may cross the placenta to the fetus and may adversely affect blood coagulation in the fetus.
Dabigatran Risks for Pregnant Women
The article, published in Obstetrics & Gynecology on May 6, 2014, describes a perfusion experiment in which researchers in Toronto, Ontario, Canada used six placentas obtained from healthy term pregnancies following Cesarean deliveries at a local hospital. The researchers added Pradaxa to the maternal circulation of the placentas and then sampled maternal and fetal reservoirs for transfer of the drug, carbon dioxide and oxygen content, glucose consumption, pH and lactate production.
After three hours, researchers found that the drug crosses the human placenta relatively slowly. However, from a clinical perspective, scientists stated that the medication should not be used for anticoagulation of pregnant women until further research can be done to determine the extent of dabigatran risks, as the drug may have a negative effect on fetal blood coagulation.
Pradaxa, introduced in the U.S. in October 2010, was first approved for patients with atrial fibrillation. According to Boehringer Ingelheim Pharmaceuticals, the drug was intended to thin the patient’s blood and reduce the risk of heart attack, stroke and death. While the medication was later approved to treat deep vein thrombosis and pulmonary embolisms, patients throughout the U.S. are currently filing lawsuits against the manufacturer, claiming that they experienced serious and life-threatening complications including internal bleeding. Although other blood thinning medications such as warfarin may cause these conditions and can be reversed with an antidote such as vitamin K, there is no such remedy to stop internal bleeding complications that may arise from Pradaxa use.
A recent update in the nation’s multidistrict litigation in the U.S. District Court, Southern District of Illinois reports that the first bellwether trial in which plaintiffs allege dabigatran risks (a.k.a. Pradaxa) is scheduled to begin on September 8, 2014. According to an investigative report launched by 7 Action News in Detroit in February 2014, the U.S. Food and Drug Administration received 1,158 reports of deaths and 12,494 reports of injuries since Pradaxa was first approved.
Contact the American Injury Attorney Group Today
If you or someone you love has suffered from complications while taking Pradaxa or have concerns about the potential dabigatran risks, contact the American Injury Attorney Group. We can evaluate your case at no cost to you and connect you with an affiliated attorney who can file your lawsuit and help you seek the compensation to which you may be entitled.